Overview Dividends

(SIBN) Si-Bone - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8257041090

Implants, Screws, Plates, Instruments

SIBN EPS (Earnings per Share)

EPS Growth (3Y CAGR): 165.21%
EPS Trend (3Y Correlation): 93.0%

SIBN Revenue

Revenue Growth (3Y CAGR): 24.82%
Revenue Trend (3Y Correlation): 96.5%

Risk via 10d forecast
Volatility	49.5%
Value at Risk 5%th	73.5%
Relative Tail Risk	-9.71%

Reward TTM
Sharpe Ratio	0.37
Alpha	-3.85

Character TTM
Hurst Exponent	0.463
Beta	0.857
Beta Downside	0.737

Drawdowns 3y
Max DD	58.72%
Mean DD	33.95%
Median DD	%

Description: SIBN Si-Bone October 22, 2025

SI-BONE, Inc. (NASDAQ: SIBN) develops and sells minimally invasive implant systems that treat sacroiliac (SI) joint dysfunction, pelvic trauma, and related spinal-fusion indications. Its product portfolio centers on the iFuse family-including iFuse-3D (a 3-D-printed porous titanium implant), iFuse TORQ (threaded trauma implants), iFuse Bedrock Granite (fusion and fixation platform), and iFuse INTRA (cell-based therapies)-which it markets primarily through a direct sales force supplemented by third-party agents.

Founded in 2008 and headquartered in Santa Clara, California, SI-BONE operates in the U.S. and select international markets. The company is classified under GICS “Health Care Supplies” and focuses on the niche but growing sacropelvic device segment, which analysts estimate to be a $1.5 billion market globally, driven by an aging population and rising rates of low-back pain diagnoses.

Recent financials show FY 2023 revenue of approximately $150 million, representing a 22 % year-over-year increase, while gross margins have hovered near 78 %-a level typical for high-margin implant manufacturers. The firm’s pipeline includes a next-generation 3-D-printed SI joint implant slated for FDA clearance in 2025, which could expand its addressable market by an estimated 15 % if reimbursement pathways remain favorable.

Given the company’s strong margin profile, expanding product pipeline, and the broader macro trend of increasing minimally invasive spine procedures, a closer look at its valuation multiples and cash-flow outlook is warranted; the ValueRay platform offers a concise dashboard that can help you assess whether SIBN’s current price reflects its growth potential.

SIBN Stock Overview

Market Cap in USD	680m
Sub-Industry	Health Care Supplies
IPO / Inception	2018-10-17
Return 12m vs S&P 500	15.3%
Analyst Rating	4.56 of 5

SIBN Dividends

Currently no dividends paid

SIBN Growth Ratios

CAGR 3y	11.23%
CAGR/Max DD Calmar Ratio	0.19
CAGR/Mean DD Pain Ratio	0.33
Current Volume	523.1k
Average Volume	358.9k

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (-23.8m TTM) > 0 and > 6% of Revenue (6% = 11.1m TTM)

FCFTA -0.06 (>2.0%) and ΔFCFTA 6.09pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 98.62% (prev 119.6%; Δ -21.00pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.01 (>3.0%) and CFO -3.26m > Net Income -23.8m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 8.38 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (42.8m) change vs 12m ago 3.56% (target <= -2.0% for YES)

Gross Margin 79.45% (prev 77.69%; Δ 1.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 81.48% (prev 67.33%; Δ 14.15pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -6.91 (EBITDA TTM -15.8m / Interest Expense TTM 3.00m) >= 6 (WARN >= 3)

Altman Z'' -9.38

(A) 0.79 = (Total Current Assets 207.4m - Total Current Liabilities 24.8m) / Total Assets 230.9m

(B) -1.92 = Retained Earnings (Balance) -444.0m / Total Assets 230.9m

warn (B) unusual magnitude: -1.92 — check mapping/units

(D) -7.32 = Book Value of Equity -443.4m / Total Liabilities 60.6m

Total Rating: -9.38 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 40.31

1. Piotroski 2.0pt = -3.0

2. FCF Yield -2.23% = -1.11

3. FCF Margin -6.87% = -2.58

4. Debt/Equity 0.22 = 2.48

5. Debt/Ebitda -0.18 = -2.50

6. ROIC - WACC (= -16.61)% = -12.50

7. RoE -14.20% = -2.37

8. Rev. Trend 96.53% = 7.24

9. EPS Trend 93.04% = 4.65

What is the price of SIBN shares?

As of November 14, 2025, the stock is trading at USD 17.26 with a total of 523,086 shares traded.
Over the past week, the price has changed by +13.63%, over one month by +15.53%, over three months by +9.94% and over the past year by +31.35%.

Is Si-Bone a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Si-Bone (NASDAQ:SIBN) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 40.31 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SIBN is around 14.87 USD . This means that SIBN is currently overvalued and has a potential downside of -13.85%.

Is SIBN a buy, sell or hold?

Si-Bone has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy SIBN.

Strong Buy: 5
Buy: 4
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the SIBN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	24.8	43.6%
Analysts Target Price	24.8	43.6%
ValueRay Target Price	16.6	-3.9%

SIBN Fundamental Data Overview November 11, 2025

Market Cap USD = 680.3m (680.3m USD * 1.0 USD.USD)
P/S = 3.6723
P/B = 3.6241
Beta = 0.789
Revenue TTM = 185.3m USD
EBIT TTM = -20.8m USD
EBITDA TTM = -15.8m USD
Long Term Debt = 35.5m USD (from longTermDebt, last quarter)
Short Term Debt = 1.11m USD (from shortTermDebt, last quarter)
Debt = 36.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.78m USD (from netDebt column, last quarter)
Enterprise Value = 571.7m USD (680.3m + Debt 36.9m - CCE 145.5m)
Interest Coverage Ratio = -6.91 (Ebit TTM -20.8m / Interest Expense TTM 3.00m)
FCF Yield = -2.23% (FCF TTM -12.7m / Enterprise Value 571.7m)
FCF Margin = -6.87% (FCF TTM -12.7m / Revenue TTM 185.3m)
Net Margin = -12.83% (Net Income TTM -23.8m / Revenue TTM 185.3m)
Gross Margin = 79.45% ((Revenue TTM 185.3m - Cost of Revenue TTM 38.1m) / Revenue TTM)
Gross Margin QoQ = 79.80% (prev 79.71%)
Tobins Q-Ratio = 2.48 (Enterprise Value 571.7m / Total Assets 230.9m)
Interest Expense / Debt = 1.80% (Interest Expense 666.0k / Debt 36.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -16.4m (EBIT -20.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.38 (Total Current Assets 207.4m / Total Current Liabilities 24.8m)
Debt / Equity = 0.22 (Debt 36.9m / totalStockholderEquity, last quarter 170.3m)
Debt / EBITDA = -0.18 (negative EBITDA) (Net Debt 2.78m / EBITDA -15.8m)
Debt / FCF = -0.22 (negative FCF - burning cash) (Net Debt 2.78m / FCF TTM -12.7m)
Total Stockholder Equity = 167.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.29% (Net Income -23.8m / Total Assets 230.9m)
RoE = -14.20% (Net Income TTM -23.8m / Total Stockholder Equity 167.4m)
RoCE = -10.23% (EBIT -20.8m / Capital Employed (Equity 167.4m + L.T.Debt 35.5m))
RoIC = -8.08% (negative operating profit) (NOPAT -16.4m / Invested Capital 203.0m)
WACC = 8.53% (E(680.3m)/V(717.3m) * Re(8.92%) + D(36.9m)/V(717.3m) * Rd(1.80%) * (1-Tc(0.21)))
Discount Rate = 8.92% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.69%
Fair Price DCF = unknown (Cash Flow -12.7m)
EPS Correlation: 93.04 | EPS CAGR: 165.2% | SUE: 4.0 | # QB: 3
Revenue Correlation: 96.53 | Revenue CAGR: 24.82% | SUE: 0.51 | # QB: 0

Additional Sources for SIBN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle